Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.39 |
| ▸ | GLP1R | P43220 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692695 | 1.00 | ESR1 (0.42) | ESR1HCAR3GLP1RALDH1A1TDP1 | |
| SCHEMBL252101 | 1.00 | ESR1 (0.42) | ESR1HCAR3GLP1RALDH1A1TDP1 | |
| SCHEMBL250479 | 0.85 | ESR1 (0.40) | ESR1HCAR3HRH4 | |
| SCHEMBL251409 | 0.84 | ESR1 (0.40) | ESR1TDP1HRH4GAA | |
| SCHEMBL252097 | 0.84 | ESR1 (0.40) | ESR1TDP1HRH4GAA | |
| SCHEMBL17344039 | 0.83 | ESR1 (0.44) | ESR1HCAR3GLP1RALDH1A1TDP1 | |
| SCHEMBL21996579 | 0.83 | ESR1 (0.44) | ESR1HCAR3GLP1RALDH1A1TDP1 | |
| SCHEMBL15907429 | 0.83 | ESR1 (0.44) | ESR1HCAR3GLP1RALDH1A1TDP1 | |
| SCHEMBL179532 | 0.82 | HRH4 (0.46) | ESR1ALDH1A1TDP1L3MBTL1HRH4 | |
| SCHEMBL251805 | 0.80 | HCAR3 (0.39) | HCAR3GLP1RALDH1A1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441392-B1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | INTELLIKINE LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3441392-A1 | A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Intellikine, LLC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3150609-A1 | PROCESS FOR PREPARING CERTAIN CHEMICAL ENTITIES | Intellikine, LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9527847-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140343057-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2014-11-20 | — | — | US | disclosed |
| US-8828998-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2012-09-27 | — | — | US | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140377258-A1 | Treatment Of Cancers Using PI3 Kinase Isoform Modulators | PIK3CA, MCL1, PIK3CB | ESR1 2071/4885HCAR3 2928/4885GLP1R 3719/4885 |
| US-20140343057-A1 | TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS | MYLK2, SSB, MYLK | ESR1 3919/4885HCAR3 3475/4885GLP1R 3422/4885 |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | ESR1 1648/4885HCAR3 1689/4885GLP1R 3503/4885 |
| US-20120245169-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ESR1 1215/4885HCAR3 1330/4885GLP1R 2180/4885 |
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | ESR1 791/4885HCAR3 2857/4885GLP1R 1253/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | ESR1 1135/4885HCAR3 1549/4885GLP1R 3668/4885 |
| US-20140341894-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | ESR1 1135/4885HCAR3 1549/4885GLP1R 3668/4885 |
| US-20150283142-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ESR1 2071/4885HCAR3 2928/4885GLP1R 3719/4885 |
| US-20160158239-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | ESR1 1135/4885HCAR3 1549/4885GLP1R 3668/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ESR1 2071/4885HCAR3 2928/4885GLP1R 3719/4885 |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ESR1 2071/4885HCAR3 2928/4885GLP1R 3719/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | ESR1 1215/4885HCAR3 1330/4885GLP1R 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.